You are here:

Quetiapine (Seroquel)


Following a full submission.

Quetiapine (Seroquel) is accepted for use within NHS Scotland for the treatment of manic episodes associated with bipolar disorder as monotherapy or as adjunct therapy to mood stabilisers.

Active comparators were included in the monotherapy trials but the studies were not designed to show differences between active comparator and quetiapine. It has not been compared to other atypical antipsychotics in this indication. Economic data suggest that quetiapine (Seroquel) is at least cost neutral, compared to other licensed approaches using atypical antipsychotics in this indication, either as adjunctive therapy or monotherapy.

Drug Details

Drug Name: Quetiapine (Seroquel)
SMC Drug ID: 104/04
Manufacturer: AstraZeneca UK Ltd
Indication: Manic episodes associated with bipolar disorder
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 July 2004